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Background
Most HIV transmission occurs on the mucosal surfaces of
the gastrointestinal and cervico-vaginal tracts, which are
coated by a biofilm of commensal bacteria. We are genet-
ically engineering such naturally occurring bacteria to
secrete peptides that block viral infection or replication.
Introduction of such genetically modified organisms into
uninfected individuals under conditions where they colo-
nize the mucosa would provide a long lasting bioshield
against HIV.
Materials and methods
Nissle 1917, a highly colonizing probiotic strain of E. coli,
was genetically engineered to secrete an HIV fusion-block-
ing peptide through the hemolysin A secretion pathway.
Lactobacillus jensenii 1153, a natural vaginal isolate, was
modified to secrete the same peptide via the S-protein
layer secretion pathway.
Results
By using a combination of cis- and trans-acting regulatory
signals, micromolar secretion levels of the anti-HIV pep-
tide were achieved in Nissle 1917. In vitro the genetically
engineered E. coli potently blocked infection of T cells and
macrophage by a wide spectrum of HIV primary isolates.
In vivo, the modified strain colonized the lower intestine
of rhesus macaques, and protected 50% of animals
against rectal infection by pathogenic SHIV162p3 in a
small cohort of animals challenged shortly following col-
onization. Genetically engineered L. jensenii also secreted
fusion-inhibitor peptide and colonized the vagina in
estrus phase mice and in macaques.
Conclusion
Our data demonstrate the potential of genetically modi-
fied commensal bacteria to provide cheap, effective pro-
tection against HIV infection.
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